HAI-ROBOTICS
23.5.2022 10:44:09 CEST | Business Wire | Press release
HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems for warehouse logistics, will exhibit its cutting-edge automation technology at LogiMAT 2022, Europe's biggest annual intralogistics tradeshow, from May 31 to June 2 in Stuttgart, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005089/en/
The company will show how the ACR systems, a highly flexible goods-to-person solution that improves operation efficiency and storage density, could meet the current needs of Europe's warehouses and distribution centers.
The live demo at Booth D71, Hall 3 will be led by HAIPICK A42T, the tallest robot in HAI ROBOTICS' ACR systems that can reach a max picking height of 10-meters. Featuring a telescopic lift, the robot can also descend to as low as 0.28m to pick totes and cartons stored on the bottom level of the shelf. It can carry 8 loads to feed HAIPORT, goods-to-person workstation, in one move. The robot has been titled the "Best in Intralogistics" in IFOY 2021.
HAIPORT, also to be displayed at LogiMAT, is another warehousing efficiency and throughput booster. With the ability to load four to eight cases in only three seconds from a robot, and unload the same number of cases in five seconds at the same time, a single workstation is able to handle up to 900 cases per hour, an order-fulfillment speed that is 16 times faster than robot-to-conveyor belt transport.
ACR systems, "much more attractive"
HAI ROBOTICS sees the ACR systems a good fit for European users, especially in the age of e-commerce when more consumers are longing for faster deliveries and omni-channel shopping experience.
Mr Kai Ramadhin, the company's VP of Sales & Marketing Europe, said: "HAI ROBOTICS solution provides more flexibility in terms of expansion ability, rapid deployment times and so on. So the sweet-spot of our solution is much more attractive."
Mr Ramadhin noted the company is focused on creating a local network of system integrator, installation and service partners, so that any user of ACR systems can expect rapid and high-quality service wherever they are in Europe.
Since setting up its regional headquarters in the Netherlands in late 2021, HAI ROBOTICS has built a strong localized network in countries of France, Germany, Spain, Italy, the Benelux and the U.K.
The ACR systems are presented by its global partner Savoye at Log!Ville in Belgium in an initiative to make the high-density warehousing technology widely known to the European supply chain. The company has also teamed up with U.K.-based Invar System and Greece's Voyatzoglou Systems to enable tailored service accessible to regional business operators.
When the market gets increasingly dynamic and volatile, the company sees the systems can bring users some key benefits, including:
1. Alleviating labor challenges
Through the automation of practices, warehouses can meet the demands of the modern world by improving employee productivity and filling job vacancies, when recruiting and retaining gets tough.
Robots also free workers from doing repetitive and labour intensive work in the warehouse. The ACR systems, for example, save a worker 40,000 to 60,000 steps of walking per day, on average, according to the company's statistics.
2. Storage space utilization to save land investment
As warehouse ceiling heights have continuously risen, the ACR systems, with the max picking height reaching 10 meters, allow the warehouse to easily use the upper storage space. That may also save the user investment in warehouse expansion, in particular in countries where land costs are high.
3. Fast & flexible implementation, more affordable
Business owners are facing a fast-changing and less predictable market nowadays than ever before. The growing customer expectations for faster deliveries and omni-channel shopping experience are driving companies to rethink their supply-chain operating models. The ACR systems have the high level of flexibility to allow a project to be deployed within months, and can be easily scaled according to business volume. A warehouse owner can choose to scale operation by adding or removing robots without disrupting any ongoing operations since the ACR systems require no structural changes to an existing facility.
That also means the systems are more affordable, especially for smaller businesses.
In Europe, many small-to-medium-sized enterprises see a need for automation, but their limited budget does not allow them to spend years implementing large projects. The ACRs turn out to be a fit in that case too.
ACR systems allow any business to start automation small, and grow as business grows. Many of its subscribers started to customize their solutions with a few robots and adding more when their demand expands.
4. Ideal for the age of e-commerce
In the age of e-commerce, businesses across the globe need to deal with flurries of online orders, which often come scattered and in large numbers. Plus the need to shorten delivery time to improve customer satisfaction, they need to significantly boost the order-fulfilment speed of their warehouses and DCs.
E-grocery emerges to be the channel embracing the growth capabilities. According to McKinsey, e-grocery channel grew by more than 50 percent in 2020 - compared to 2019 growth - for key European markets, creating an even stronger need for efficient e-grocery fulfillment solutions. Smaller unit picks, mixed orders, and a high speed of delivery make e-grocery labor intensive and therefore ideal for automation.
The ACR systems can boost order-fulfillment efficiency when handling large SKU portfolio as well as small orders with a high share of single-unit picks in e-grocery warehouses.
In several micro-fulfillment centers in Europe, the ACR systems have been implemented to handle home-delivery orders as well as click-and-collect orders with contactless deliveries over the counter at the storefront.
ABOUT HAI ROBOTICS
HAI ROBOTICS, the pioneer in Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Australia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220522005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
